Learn about the emerging treatment options for AMD. Here are the new treatments—such as pipeline therapies, biosimilar alternatives, novel intravitreal agents, and sustained drug delivery systems—that will receive significant attention in the next year.
With myopia becoming a major public health concern in many countries, an emphasis on prevention may prove to best serve patients in the future. Learn the latest on the evolving landscape of myopia prevention.
The OHTS 20-year follow-up supports the standard of care of using topical ocular hypotensive medications to prevent glaucoma progression in moderate and high-risk patients with ocular hypertension.
In the past three decades, there have been major advancements in the diagnosis and treatment of inherited retinal diseases, including novel gene therapies. Here's what ophthalmologists should know about these new treatment options.
Diabetic eye disease remains a major cause of vision loss in patients with diabetes. Here, we present the role of corticosteroids in suppressing chronic inflammation and tissue injury specific to DME in the diabetic patient population.